title: Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease.
authors.forename: Karthik
authors.initials: K
authors.lastname: Ramasamy
authors.forename: Beth
authors.initials: B
authors.lastname: Hazel
authors.forename: Shameem
authors.initials: S
authors.lastname: Mahmood
authors.forename: Sophie
authors.initials: S
authors.lastname: Corderoy
authors.forename: Stephen
authors.initials: S
authors.lastname: Schey
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069461:Bendamustine Hydrochloride; D003907:Dexamethasone / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000503:physiopathology*; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage; D013792:Thalidomide / Q000008:administration & dosage
chemical_list: D009588:Nitrogen Mustard Compounds; D013792:Thalidomide; D003907:Dexamethasone; D000069461:Bendamustine Hydrochloride